vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Zeo Energy Corp. (ZEO). Click either name above to swap in a different company.
Zeo Energy Corp. is the larger business by last-quarter revenue ($18.6M vs $10.7M, roughly 1.7× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -10.8%, a 34.3% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs -0.4%). Over the past eight quarters, Zeo Energy Corp.'s revenue compounded faster (-4.0% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
ABUS vs ZEO — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $18.6M |
| Net Profit | $2.5M | $-2.0M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | -11.8% |
| Net Margin | 23.5% | -10.8% |
| Revenue YoY | 522.2% | -0.4% |
| Net Profit YoY | 112.7% | -360.9% |
| EPS (diluted) | $0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $18.6M | ||
| Q3 25 | — | $23.9M | ||
| Q2 25 | $10.7M | $18.1M | ||
| Q1 25 | — | $8.8M | ||
| Q4 24 | — | $18.6M | ||
| Q3 24 | — | $19.7M | ||
| Q2 24 | — | $14.8M | ||
| Q1 24 | — | $20.1M |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-3.2M | ||
| Q2 25 | $2.5M | $-2.4M | ||
| Q1 25 | — | $-6.4M | ||
| Q4 24 | — | $-435.3K | ||
| Q3 24 | — | $-424.3K | ||
| Q2 24 | — | $-277.8K | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | 57.9% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 99.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 50.2% | ||
| Q2 24 | — | 52.3% | ||
| Q1 24 | — | — |
| Q4 25 | — | -11.8% | ||
| Q3 25 | — | -8.3% | ||
| Q2 25 | 13.9% | -15.8% | ||
| Q1 25 | — | -153.8% | ||
| Q4 24 | — | -6.0% | ||
| Q3 24 | — | -15.2% | ||
| Q2 24 | — | -18.0% | ||
| Q1 24 | — | -20.1% |
| Q4 25 | — | -10.8% | ||
| Q3 25 | — | -13.5% | ||
| Q2 25 | 23.5% | -13.3% | ||
| Q1 25 | — | -72.4% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | -2.2% | ||
| Q2 24 | — | -1.9% | ||
| Q1 24 | — | -7.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0.01 | — | ||
| Q1 25 | — | $-0.48 | ||
| Q4 24 | — | $1.11 | ||
| Q3 24 | — | $-0.08 | ||
| Q2 24 | — | $0.03 | ||
| Q1 24 | — | $-1.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $6.1M |
| Total DebtLower is stronger | $0 | $79.1K |
| Stockholders' EquityBook value | $83.0M | $5.3M |
| Total Assets | $103.3M | $56.9M |
| Debt / EquityLower = less leverage | 0.00× | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $6.1M | ||
| Q3 25 | — | $3.9M | ||
| Q2 25 | $37.4M | $68.7K | ||
| Q1 25 | — | $2.9M | ||
| Q4 24 | — | $5.6M | ||
| Q3 24 | — | $4.3M | ||
| Q2 24 | — | $5.3M | ||
| Q1 24 | — | — |
| Q4 25 | — | $79.1K | ||
| Q3 25 | — | $84.6K | ||
| Q2 25 | $0 | $642.8K | ||
| Q1 25 | — | $715.4K | ||
| Q4 24 | — | $787.7K | ||
| Q3 24 | — | $858.6K | ||
| Q2 24 | — | $1.6M | ||
| Q1 24 | — | $748.8K |
| Q4 25 | — | $5.3M | ||
| Q3 25 | — | $-1.7M | ||
| Q2 25 | $83.0M | $-59.4M | ||
| Q1 25 | — | $-23.1M | ||
| Q4 24 | — | $-88.9M | ||
| Q3 24 | — | $-39.3M | ||
| Q2 24 | — | $-53.0M | ||
| Q1 24 | — | $-173.0M |
| Q4 25 | — | $56.9M | ||
| Q3 25 | — | $58.5M | ||
| Q2 25 | $103.3M | $46.2M | ||
| Q1 25 | — | $47.4M | ||
| Q4 24 | — | $61.0M | ||
| Q3 24 | — | $47.1M | ||
| Q2 24 | — | $49.1M | ||
| Q1 24 | — | $50.1M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $2.4M |
| Free Cash FlowOCF − Capex | — | $2.3M |
| FCF MarginFCF / Revenue | — | 12.2% |
| Capex IntensityCapex / Revenue | 0.0% | 0.9% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-9.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $-6.6M | ||
| Q2 25 | $-15.7M | $-2.3M | ||
| Q1 25 | — | $-2.3M | ||
| Q4 24 | — | $3.5M | ||
| Q3 24 | — | $162.2K | ||
| Q2 24 | — | $-2.2M | ||
| Q1 24 | — | $-10.2M |
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $-6.8M | ||
| Q2 25 | — | $-2.7M | ||
| Q1 25 | — | $-2.6M | ||
| Q4 24 | — | $3.4M | ||
| Q3 24 | — | $116.5K | ||
| Q2 24 | — | $-2.3M | ||
| Q1 24 | — | $-10.4M |
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | -28.6% | ||
| Q2 25 | — | -15.0% | ||
| Q1 25 | — | -30.0% | ||
| Q4 24 | — | 18.2% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | -15.6% | ||
| Q1 24 | — | -51.5% |
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | 0.0% | 2.4% | ||
| Q1 25 | — | 4.2% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
ZEO
| Nonrelated Party | $18.1M | 98% |
| Related Party | $432.1K | 2% |
